Frankfurt
26.11.25 | 15:29
1,664 Euro
-2,00 % -0,034
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Advicenne Has Submitted to US FDA the Registration Application for Sibnayal in dRTA Treatment | 272 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11. | ADVICENNE: Advicenne has submitted to the US FDA the registration application (NDA) for Sibnayal in dRTA treatment | 3 | Euronext | ||
| 07.10. | ADVICENNE: Advicenne reports First Half financial results as of June 30, 2025, and updates on its activities | 3 | Euronext | ||
| 19.09. | Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities | 343 | Business Wire | Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million
H1 products sales and royalties totaled €3.1 million, up 20%
Financial visibility extended to the fourth... ► Artikel lesen | |
| 26.08. | Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103 | 288 | Business Wire | This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025
Regulatory News:
Advicenne (Euronext Growth Paris... ► Artikel lesen | |
| 28.07. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in Saudi Arabia | 398 | Business Wire | Regulatory News:
Advicenne (Euronext Growth® FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare... ► Artikel lesen | |
| 25.07. | Advicenne Reports its H1 2025 Sales | 362 | Business Wire | Regulatory News:
Advicenne (Euronext Growth FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney... ► Artikel lesen | |
| 21.07. | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 771 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 02.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 361 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 30.06. | Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue. | 388 | Business Wire | Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches... ► Artikel lesen | |
| 29.04. | Advicenne 2024 Universal Registration Document Made Available | 278 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 27.03. | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 561 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
| 29.01. | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 483 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 23.01. | Advicenne Announces 2024 Gross Sales1 | 471 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
| 19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 515 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 28.11.24 | Advicenne Announces its 2025 Financial Calendar | 230 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,210 | -0,11 % | Pfizer-Aktie: Konzern kämpft gegen Kursdruck | Pfizer ist die aktuell vielleicht interessanteste Dividenden-Aktie im Pharmasektor. Während Shortseller den Titel immer wieder unter Druck setzen, deuten operative Fortschritte und neue strategische... ► Artikel lesen | |
| ABBVIE | 197,20 | -1,65 % | Psychedelische Medizin rückt ins Zentrum - wie Bioxyne, AbbVie und Johnson & Johnson den Weg für neue Therapien ebnen könnten | ||
| HAEMATO | 8,800 | +2,92 % | EQS-Adhoc: M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group | EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e): Verkauf/Beteiligung/Unternehmensbeteiligung
M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group
16.10.2025... ► Artikel lesen | |
| HALEON | 4,233 | -0,61 % | Altibbi Enables Haleon's "Healthy Saudi Smile" Campaign, Turning Oral Health Awareness Into Action | RIYADH, Saudi Arabia, Nov. 24, 2025 /PRNewswire/ -- Altibbi, the leading digital-health platform in the Arab world, partnered with Haleon, the global consumer health company behind brands... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 177,00 | +0,57 % | Ligand Pharma: RBC bekräftigt "Outperform"-Rating vor Investorentag | ||
| ACHIEVE LIFE SCIENCES | 4,165 | +4,78 % | Citizens initiates Achieve Life Sciences stock with Market Outperform rating | ||
| ROYALTY PHARMA | 34,100 | -0,26 % | Dividendenbekanntmachungen (14.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3M COMPANY US88579Y1010 0,73 USD 0,6273 EUR AGCO CORPORATION US0010841023 0,29 USD 0,2492 EUR ALBEMARLE CORPORATION PREF A US0126532003 0... ► Artikel lesen | |
| EISAI | 28,000 | +2,34 % | Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status | LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this... ► Artikel lesen | |
| TG THERAPEUTICS | 28,345 | -0,60 % | Director At TG Therapeutics Sells $162K Of Stock | ||
| DR REDDYS | 11,900 | -0,83 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| BETTERLIFE PHARMA | 0,025 | -9,26 % | Betterlife Pharma Inc (2): Betterlife appoints Carcillo as corporate adviser | ||
| IGC PHARMA | 0,286 | +4,38 % | IGC Pharma, Inc.: IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends | POTOMAC, MD / ACCESS Newswire / November 25, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative... ► Artikel lesen | |
| KYOWA KIRIN | 14,500 | -2,03 % | Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | - NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients - - Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 6,550 | +1,55 % | Wave Life Sciences Ltd.: Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update | WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding... ► Artikel lesen | |
| IMMUPHARMA | 0,080 | 0,00 % | ImmuPharma shares fall as P140 deal time-frame extended to 2026 |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.